Clinical trial
A Phase II Study of Perifosine Plus Imatinib Mesylate for Patients With Resistant Gastrointestinal Stromal Tumor
NCT00455559 is registered in ClinicalTrials.gov with AEterna Zentaris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Perifosine Plus Imatinib Mesylate for Patients With Resistant Gastrointestinal Stromal Tumor
- Lead sponsor
- AEterna Zentaris
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2006
- Completion date
- October 31, 2011
- Enrollment
- 40 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.